Janelle Zeihen worried she’d have to file for bankruptcy after learning she owed $250,000 for her Crohn’s disease treatment.  The Milwaukee nursing home worker thought her insurance was covering the ...

It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a ...

Q1 2025 Earnings Call Transcript April 25, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.46, expectations ...

AbbVie Inc. (NYSE:ABBV) reported an earnings per share (EPS) of $2.46, beating the estimated $2.38 and marking a 2.93% ...

AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in ...

As of Thursday’s close, the S&P 500 has a week-to-date gain of nearly 4%, the Dow Jones Industrial Average is up more than 2% ...

AbbVie has kicked off the year with a resounding success, exceeding expectations across multiple therapeutic areas. The ...

AbbVie stock inched higher Friday after the pharma titan hiked its outlook on the back of strength from its immunology ...

AbbVie took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

AbbVie (NYSE:ABBV) recently announced its first-quarter earnings, reporting increased sales year-on-year while experiencing a ...

While management did not quantify any potential tariff exposure, it did signal that the effect would be in line with the ...